MSTN and sarcopenia: Myostatin is a known regulator of muscle mass and has been examined as a therapeutic target to ameliorate symptoms of dystrophy, cachexia, and sarcopenia (Rodgers and Garikipati, 2008; Sartori et al., 2013; Mouisel et al., 2014).